Analysts are expressing optimism over Abiomed (NSDQ:ABMD) after the company’s third-quarter results saw its stock soar yesterday.
Upon releasing the quarterly report, Abiomed’s stock rose 12.4% at $369.45 in the early morning yesterday. The stock price rose as high as $387.23 yesterday but has since dropped to $341.42 at midday today.
Jefferies analysts released a report highlighting the long-term growth prospects for Abiomed’s Impella heart pump for high-risk percutaneous coronary intervention (PCI) and the strength of the company’s position as it navigates through the COVID-19 pandemic.
Even with COVID-19-related headwinds, Abiomed offered improved guidance for revenue growth between 9% and 14% in the fourth quarter, leading the analysts to feel bullish about the company’s prospects and list it as a “buy” option.
Additionally, analysts are buoyed by Abiomed’s reports of ahead-of-schedule technologi…